Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rein TherapeuticsRNTX +1.96%31 Cash Ratio is 4.19 as of Jun. 2026, which is at its 10-year median of 4.19. GuruFocus rates RNTX with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,376 Biotechnology companies, Rein Therapeutics ranks better than 59.01% on this metric.
Rein Therapeutics has a Cash Ratio of 4.19. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Rein Therapeutics's Cash Ratio or its related term are showing as below:
RNTX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.33 Med: 4.19 Max: 20.62
Current: 4.19
During the past 11 years, Rein Therapeutics's highest Cash Ratio was 20.62. The lowest was 0.33. And the median was 4.19.
RNTX's Cash Ratio is ranked better than 59.01% of 1376
companies
in the Biotechnology industry
Industry Median: 2.96
vs RNTX: 4.19
Rein Therapeutics (NAS:RNTX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Rein Therapeutics Cash Ratio Related Terms
Rein Therapeutics Cash Ratio Historical Data
* Premium members only.
The historical data trend for Rein Therapeutics's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rein Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rein Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rein Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Rein Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rein Therapeutics (RNTX) has a Cash Ratio of 4.19 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rein Therapeutics and its competitors. This is near median its historical median of 4.19. Over the past decade, Rein Therapeutics' Cash Ratio has ranged from 0.33 to 20.62. According to the industry distribution chart, Rein Therapeutics ranks #564 out of 1376 companies in the Biotechnology industry, placing it in the top 41%.
Is Rein Therapeutics' Cash Ratio too high?
Rein Therapeutics' current Cash Ratio of 4.19 is near median its 10-year median of 4.19. Over the past 10 years, this metric has ranged from a low of 0.33 to a high of 20.62. The Biotechnology industry median Cash Ratio is 2.96. Rein Therapeutics' value of 4.19 is 41.6% above this industry median. Based on the distribution chart, Rein Therapeutics ranks #564 out of 1376 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rein Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' Cash Ratio compare to BSEM and OSTX?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #564 out of 1376 companies for Cash Ratio. This puts Rein Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.96. Rein Therapeutics' value of 4.19 is 41.6% above this benchmark. Historically, Rein Therapeutics' own Cash Ratio has ranged from 0.33 to 20.62 over the past decade. While the company's 10-year median is 4.19 vs. the industry median of 2.96, Rein Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,376 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rein Therapeutics's current Cash Ratio of 4.19 is 41.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Rein Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rein Therapeutics's current Cash Ratio is 4.19, which is near median its own 10-year median of 4.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current Cash Ratio of 4.19. The current Cash Ratio is 4.19, which is near median its 10-year median of 4.19 and 41.6% above the Biotechnology industry median of 2.96. Rein Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current Cash Ratio is 4.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
31GF Score
Get the complete analysis for RNTX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNTX has been successfully added to your 
